Your browser is no longer supported. Please, upgrade your browser.
Settings
ACER Acer Therapeutics Inc. daily Stock Chart
ACER [NASD]
Acer Therapeutics Inc.
Index- P/E- EPS (ttm)-2.45 Insider Own0.10% Shs Outstand11.58M Perf Week-22.99%
Market Cap229.63M Forward P/E89.32 EPS next Y0.22 Insider Trans- Shs Float8.12M Perf Month-13.41%
Income-21.30M PEG- EPS next Q-0.82 Inst Own59.20% Short Float2.35% Perf Quarter-20.04%
Sales- P/S- EPS this Y-31.40% Inst Trans0.12% Short Ratio4.97 Perf Half Y-16.12%
Book/sh4.48 P/B4.43 EPS next Y107.80% ROA-59.20% Target Price52.00 Perf Year5.76%
Cash/sh3.60 P/C5.51 EPS next 5Y- ROE-65.10% 52W Range16.02 - 34.10 Perf YTD-1.44%
Dividend- P/FCF- EPS past 5Y52.60% ROI- 52W High-41.85% Beta2.55
Dividend %- Quick Ratio7.70 Sales past 5Y- Gross Margin- 52W Low23.78% ATR1.48
Employees23 Current Ratio7.70 Sales Q/Q- Oper. Margin- RSI (14)32.10 Volatility10.87% 5.91%
OptionableNo Debt/Eq0.00 EPS Q/Q-113.00% Profit Margin- Rel Volume3.44 Prev Close20.56
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume38.32K Price19.83
Recom1.80 SMA20-17.41% SMA50-16.25% SMA200-18.92% Volume125,380 Change-3.55%
Feb-15-19Resumed Raymond James Outperform $40
Dec-20-18Initiated Needham Buy $48
Feb-26-18Initiated ROTH Capital Buy
Dec-20-17Initiated H.C. Wainwright Buy $50
Apr-16-19 08:30AM  Acer Therapeutics Announces Publication of Vascular Ehlers-Danlos Syndrome (vEDS) Patient Registry Data GlobeNewswire
Apr-05-19 12:36PM  Introducing Acer Therapeutics (NASDAQ:ACER), A Stock That Climbed 27% In The Last Year Simply Wall St.
Mar-13-19 08:30AM  Acer Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire
Mar-07-19 04:01PM  Acer Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update GlobeNewswire
Jan-02-19 08:30AM  Acer Therapeutics Announces In-license of Osanetant from Sanofi GlobeNewswire +6.61%
Dec-26-18 04:09PM  Is This Biotech Stock Turning A Corner? Acer Pops On FDA Acceptance Investor's Business Daily +11.30%
08:30AM  Acer Therapeutics Announces FDA Acceptance of NDA and Priority Review for EDSIVO for the Treatment of vEDS GlobeNewswire
Dec-20-18 06:26AM  Opexa Therapeutics Enters Oversold Territory Zacks
Dec-17-18 08:30AM  Acer Therapeutics Appoints Salma Jutt as Chief Commercial Officer GlobeNewswire
Nov-09-18 04:01PM  Acer Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Nov-08-18 08:30AM  Acer Therapeutics to Present at the Evercore ISI HealthConX Conference GlobeNewswire
Oct-29-18 08:30AM  Acer Therapeutics Submits NDA for EDSIVO for the Treatment of vEDS GlobeNewswire
Oct-09-18 01:46PM  Do Institutions Own Shares In Acer Therapeutics Inc (NASDAQ:ACER)? Simply Wall St.
Sep-24-18 08:30AM  Acer Therapeutics to Present at the 2018 Cantor Global Healthcare Conference GlobeNewswire
Aug-20-18 08:30AM  Acer Therapeutics to Present at the 20th Annual H.C. Wainwright Conference GlobeNewswire
Aug-16-18 04:01PM  HTG Molecular Appoints Michelle R. Griffin to its Board of Directors GlobeNewswire
Aug-13-18 04:01PM  Acer Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Aug-03-18 04:01PM  Acer Therapeutics Announces Closing of Underwritten Public Offering GlobeNewswire
Aug-01-18 09:00AM  Acer Therapeutics Announces Pricing of Underwritten Public Offering GlobeNewswire +18.28%
Jul-31-18 04:01PM  Acer Therapeutics Announces Underwritten Public Offering GlobeNewswire -7.69%
05:40AM  Opexa Therapeutics Sees Hammer Chart Pattern: Time to Buy? Zacks
Jul-03-18 10:31AM  Acer Therapeutics (ACER) Shares March Higher, Can It Continue? Zacks
May-24-18 07:45AM  Report: Developing Opportunities within Opexa Therapeutics, Federated National Holding, Hess Midstream Partners LP, Zion Oil & Gas, Omnicell, and Gladstone Land Future Expectations, Projections Moving into 2018 GlobeNewswire
May-22-18 08:43AM  Why Opexa Therapeutics (ACER) Could Shock the Market Soon Zacks
May-14-18 04:01PM  Acer Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Apr-02-18 08:25AM  New Research Coverage Highlights TOCAGEN INC, Acer Therapeutics, DMC Global, The Providence Service, WEX, and Alexander's Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Mar-07-18 04:01PM  Acer Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update GlobeNewswire
Mar-06-18 08:30AM  Acer Therapeutics to Present at the 30th Annual ROTH Conference GlobeNewswire
Feb-05-18 08:30AM  Acer Therapeutics Expands Management Team with the Appointment of Three Executives and One New Key Hire GlobeNewswire
Feb-01-18 07:55AM  New Research: Key Drivers of Growth for Guess?, Acer Therapeutics, American National Insurance, J P Morgan Chase, Juno Therapeutics, and Allergan Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Jan-31-18 08:30AM  Acer Therapeutics to Present at the LEERINK Partners 7th Annual Global Healthcare Conference GlobeNewswire
Jan-03-18 08:30AM  Acer Therapeutics to Present at the Biotech Showcase 2018 Conference GlobeNewswire +6.75%
Dec-27-17 04:01PM  Acer Therapeutics Announces Partial Exercise of Over-allotment Option in Public Offering GlobeNewswire
Dec-14-17 04:01PM  Acer Therapeutics Announces Closing of Underwritten Public Offering of Common Stock GlobeNewswire
Dec-12-17 09:00AM  Acer Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock GlobeNewswire -15.27%
Dec-11-17 04:01PM  Acer Therapeutics Announces Proposed Underwritten Public Offering of Common Stock GlobeNewswire
Nov-13-17 04:05PM  Acer Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire
Oct-12-17 08:30AM  Acer Therapeutics Welcomes Two New Members to its Board of Directors GlobeNewswire +5.35%
Oct-05-17 08:30AM  Acer Therapeutics Appoints Dr. William T. Andrews as Chief Medical Officer GlobeNewswire
Sep-25-17 08:30AM  Acer Therapeutics Reports Positive Results From Pivotal Clinical Trial of EDSIVO (celiprolol) for Treatment of Vascular Ehlers-Danlos Syndrome GlobeNewswire +10.89%
Sep-22-17 08:30AM  Acer Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes three clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; and ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders, maple syrup urine disease, and osanetant for the treatment of various neuroendocrine disorders. The company was founded in 2013 and is headquartered in Newton, Massachusetts.